Community-acquired pneumonia: is less more?

Abstract

Community-acquired pneumonia is a topic of maximum interest because it remains a leading cause of morbidity and mortality due to an infection. 1 Metlay JP Waterer GW Long AC et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200: e45-e67 Crossref PubMed Scopus (870) Google Scholar At the same time, antimicrobial resistance and antimicrobial stewardship programmes are essential issues surrounding community-acquired pneumonia. 2 Viasus D Vecino-Moreno M De La Hoz JM Carratalà J Antibiotic stewardship in community-acquired pneumonia. Expert Rev Anti Infect Ther. 2017; 15: 351-359 Crossref PubMed Scopus (15) Google Scholar , 3 Barlam TF Cosgrove SE Abbo LM et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016; 62: e51-e77 Crossref PubMed Scopus (1273) Google Scholar , 4 Postma DF van Werkhoven CH van Elden LJ et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015; 372: 1312-1323 Crossref PubMed Scopus (238) Google Scholar Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trialIn patients hospitalised with moderately severe community-acquired pneumonia, a multifaceted antibiotic stewardship intervention might safely reduce broad-spectrum antibiotic use. Full-Text PDF